Warfarin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Atrial fibrillation

• Digoxin
• Diltiazem ER
• Metoprolol tartrate

Also listed for Atrial Fibrillation (Stroke Prevention)

• Amiodarone
• Apixaban
• Dabigatran
• Metoprolol
• Rivaroxaban

Other medications in Heart & Cardiovascular

• Adenosine
• Alirocumab
• Ambrisentan
• Amlodipine
• Atenolol
• Atorvastatin
• Azilsartan
• Bempedoic Acid

About Warfarin

Warfarin is a crucial medication prescribed to prevent dangerous blood clots, protecting countless individuals from serious health complications like strokes and heart attacks. Managing chronic conditions often comes with high costs, but with TheDrugClub, members can access vital medications like warfarin with significant savings, making treatment more accessible and affordable.

Warfarin is a powerful anticoagulant medication, commonly known by its brand name Coumadin. It's prescribed to treat and prevent harmful blood clots that can form in the body. These clots can lead to serious conditions such as deep vein thrombosis (DVT), a clot typically in the leg, or pulmonary embolism (PE), a life-threatening clot that travels to the lungs. It's also vital for individuals with atrial fibrillation

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Warfarin is approved for (FDA label)

Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.

Source: Read the full FDA label on DailyMed. Label effective date: August 31, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Warfarin (FDA label)

WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ] . Perform regular monitoring of INR in all treated patients [see Dosage and Administration (2.1) ] . Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see Drug Interactions (7) ] . Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [see Patient Counseling Information (17) ] . WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. Warfarin sodium can cause major or fatal bleeding. (5.1) Perform regular monitoring of INR in all treated patients. (2.1) Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. (7) Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding. (17)

Source: FDA prescribing information (DailyMed). Set ID: 5a5b5e3a-6556-a542-e063-6294a90a6d3f. SPL document ID: 5a5b5d79-6112-f2ac-e063-6394a90a2244. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Warfarin (FDA label)

Warfarin Sodium Tablets USP, 1 mg are supplied as pink to light pink, oval shaped uncoated scored tablets with debossing ‘761’ and ‘1’ on either side of the breakline on one side and ‘AN’ on the other side. Warfarin Sodium Tablets USP, 2 mg are supplied as lavender to light lavender, oval shaped uncoated scored tablets with debossing ‘762’ and ‘2’ on either side of the breakline on one side and ‘AN’ on the other side. Warfarin Sodium Tablets USP, 2½ mg are supplied as green to light green, oval shaped uncoated scored tablets with debossing ‘763’ and ‘2½’ on either side of the breakline on one side and ‘AN’ on the other side.

Source: FDA prescribing information (DailyMed). Set ID: 5a5b5e3a-6556-a542-e063-6294a90a6d3f. SPL document ID: 5a5b5d79-6112-f2ac-e063-6394a90a2244. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Warfarin (FDA label)

The following serious adverse reactions to warfarin sodium are discussed in greater detail in other sections of the labeling: Hemorrhage [see Boxed Warning , Warnings and Precautions (5.1) , and Overdosage (10) ] Tissue Necrosis [see Warnings and Precautions (5.2) ] Calciphylaxis [see Warnings and Precautions (5.3) ] Acute Kidney Injury [see Warnings and Precautions (5.4) ] Systemic Atheroemboli and Cholesterol Microemboli [see Warnings and Precautions (5.5) ] Limb Ischemia, Necrosis, and Gangrene in Patients with HIT and HITTS [see Warnings and Precautions (5.6) ] Other Clinical Settings with Increased Risks [see Warnings and Precautions (5.8) ] Other adverse reactions to warfarin sodium include: Immune system disorders: hypersensitivity/allergic reactions (including urticaria and anaphylactic reactions) Vascular disorders: vasculitis Hepatobiliary disorders: hepatitis, elevated liver enzymes. Cholestatic hepatitis has been associated with concomitant administration of warfarin sodium and ticlopidine. Gastrointestinal disorders: nausea, vomiting, diarrhea, taste perversion, abdominal pain, flatulence, bloating Skin disorders: rash, dermatitis (including bullous eruptions), pruritus, alopecia Respiratory disorders: tracheal or tracheobronchial calcification General disorders: chills Most common adverse reactions to warfarin sodium are fatal and nonfatal hemorrhage from any tissue or organ. (6) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: 5a5b5e3a-6556-a542-e063-6294a90a6d3f. SPL document ID: 5a5b5d79-6112-f2ac-e063-6394a90a2244. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Warfarin (FDA label)

Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality.

Source: FDA prescribing information (DailyMed). Set ID: 5a5b5e3a-6556-a542-e063-6294a90a6d3f. SPL document ID: 5a5b5d79-6112-f2ac-e063-6394a90a2244. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Warfarin (FDA label)

Tissue necrosis: Necrosis or gangrene of skin or other tissues can occur, with severe cases requiring debridement or amputation. Discontinue warfarin sodium and consider alternative anticoagulants if necessary. (5.2) Calciphylaxis: Fatal and serious cases have occurred. Discontinue warfarin sodium and consider alternative anticoagulation therapy. ( 5.3 ) Acute kidney injury may occur during episodes of excessive anticoagulation and hematuria. ( 5.4 ) Systemic atheroemboli and cholesterol microemboli: Some cases have progressed to necrosis or death. Discontinue warfarin sodium if such emboli occur. ( 5.5 ) Heparin-induced thrombocytopenia (HIT): Initial therapy with warfarin sodium in HIT has resulted in cases of amputation and death. Warfarin sodium may be considered after platelet count has normalized. ( 5.6) Pregnant women with mechanical heart valves: Warfarin sodium may cause fetal harm; however, the benefits may outweigh the risks. ( 5.7 ) 5.1 Hemorrhage Warfarin sodium can cause major or fatal bleeding.

Source: FDA prescribing information (DailyMed). Set ID: 5a5b5e3a-6556-a542-e063-6294a90a6d3f. SPL document ID: 5a5b5d79-6112-f2ac-e063-6394a90a2244. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Warfarin (FDA label)

Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical (herbal) products, and inhibitors and inducers of CYP2C9, 1A2, or 3A4. ( 7 ) Consult labeling of all concurrently used drugs for complete information about interactions with warfarin sodium or increased risks for bleeding. (7) 7.1 General Information Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and alteration of the physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.

Source: FDA prescribing information (DailyMed). Set ID: 5a5b5e3a-6556-a542-e063-6294a90a6d3f. SPL document ID: 5a5b5d79-6112-f2ac-e063-6394a90a2244. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.